Deepbridge are pleased to report that Glyconics, which is part of the Deepbridge Life Sciences SEIS portfolio, have signed a hardware partner agreement with Spectrolytic, a leading developer in infared (IR) spectrometers.

A hand-held device that would give early warning of ‘acute events’- and so avoid the hospitalisation of thousands of patients with chronic obstructive pulmonary disease (COPD) - is to go into production ahead of clinical trials, which are expected for Q1 2019.

See full article here.

About Glyconics

Glyconics Ltd is aiming to develop an innovative approach to the diagnosis and monitoring of chronic and acute diseases including respiratory disease.

The Company is seeking to develop a new hand-held miniaturised device to aim to effectively diagnose and predict the exacerbation of Chronic Obstructive Pulmonary Disease (COPD) in patients at the point of care.  The Company’s aim is to optimise the hand-held, miniaturised device for easy detection of disease monitoring by healthcare workers at the point-of-care.